Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma

被引：0

作者：

Mayer, Andrea ^{[1
]}

Loeffler, Markus ^{[2
]}

Missel, Sarah ^{[1
]}

Accolla, Roberto ^{[3
]}

Ma, Yuk Ting ^{[4
]}

Chaumette, Tanguy ^{[5
]}

Heidenreich, Regina ^{[6
]}

Koenigsrainer, Alfred ^{[7
]}

Ludwig, Joerg ^{[1
]}

Alcoba, Diego ^{[1
]}

Schuster, Heiko ^{[1
]}

Gouttefangeas, Cecile ^{[2
]}

Forlani, Greta ^{[3
]}

Tagliamonte, Maria ^{[8
]}

Ascierto, Paolo Antonio ^{[9
]}

Avallone, Antonio ^{[10
]}

Borrelli, Marco ^{[8
]}

Rammensee, Hans-Georg ^{[2
]}

Sangro, Bruno ^{[11
]}

Inarrairaegui, Mercedes ^{[11
]}

Francque, Sven ^{[12
]}

Vonghia, Luisa ^{[12
]}

Gori, Stefania ^{[13
]}

Weinschenk, Tony ^{[14
]}

Reinhardt, Carsten ^{[1
]}

Gnad-Vogt, Ulrike ^{[6
]}

Singh, Harpreet ^{[14
]}

Buonaguro, Luigi ^{[8
]}

机构：

[1] Immat Biotechnol GmbH, Tubingen, Germany

[2] Eberhard Karls Univ Tubingen, Dept Immunol, Tubingen, Germany

[3] Univ Insubria, Med & Surg, Varese, Italy

[4] Univ Birmingham, Sch Immun & Infect, Birmingham, W Midlands, England

[5] Univ Nantes, Nantes, France

[6] CureVac, Tubingen, Germany

[7] Eberhard Karls Univ Tubingen, Dept Gen Visceral & Transplant Surg, Tubingen, Germany

[8] Ist Nazl Tumori IRCCS Fdn G Pascale, Canc Expt Dept, Canc Immunoregulat Unit, Naples, Italy

[9] Ist Nazl Tumori IRCCS Fdn G Pascale, Melanoma Canc Immunotherapy & Dev Therapeut Uni, Naples, Italy

[10] Ist Nazl Tumori IRCCS Fdn G Pascale, GI Oncol, Naples, Italy

[11] Clin Univ Navarra, Liver Unit, Pamplona, Spain

[12] Univ Hosp Antwerp, Div Gastroenterol & Hepatol, Edegem, Belgium

[13] Osped Sacro Cuore Don G Calabria, Negrar, Italy

[14] Immat US, Houston, TX USA

来源：

JOURNAL OF HEPATOLOGY | 2020年 / 73卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

FRI339

引用

页码：S566 / S566

页数：1

共 27 条

[21] A FIRST IN MAN PHASE I TRIAL OF IMA950 (A NOVEL MULTI-PEPTIDE VACCINE) PLUS GM-CSF IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA - DESIGN AND PRELIMINARY RESULTS OF A CANCER RESEARCH UK STUDY
Rampling, R. P.
James, A.
Mulholland, P.
Peoples, S.
Al-Salihi, O.
Twelves, C.
Halford, S.
McGuigan, L.
Ritchie, J.
Sing-Jasuja, H.
NEURO-ONCOLOGY, 2012, 14 : 6 - 6
[22] AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients
Jung, Susanne
Nelde, Annika
Maringer, Yacine
Denk, Monika
Zieschang, Lisa
Kammer, Christine
Oezbek, Melek
Martus, Peter
Hackenbruch, Christopher
Englisch, Alexander
Heitmann, Jonas S.
Salih, Helmut R.
Walz, Juliane S.
FRONTIERS IN ONCOLOGY, 2024, 14
[23] FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion
Hackenbruch, Christopher
Bauer, Jens
Heitmann, Jonas S.
Maringer, Yacine
Nelde, Annika
Denk, Monika
Zieschang, Lisa
Kammer, Christine
Federmann, Birgit
Jung, Susanne
Martus, Peter
Malek, Nisar P.
Nikolaou, Konstantin
Salih, Helmut R.
Bitzer, Michael
Walz, Juliane S.
FRONTIERS IN ONCOLOGY, 2024, 14
[24] FusionVAC22_01: A phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion
Hackenbruch, C.
Bauer, J.
Heitmann, J. S.
Maringer, Y.
Nelde, A.
Federmann, B.
Bitzer, M.
Salih, H. R.
Walz, J. S.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 127 - 127
[25] FusionVAC22_01: A phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion.
Heitmann, Jonas S.
Bitzer, Michael
Hackenbruch, Christopher
Bauer, Jens
Maringer, Yacine
Nelde, Annika
Salih, Helmut R.
Walz, Juliane S.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[26] FusionVAC22_01: A phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion.
Bitzer, Michael
Hackenbruch, Christopher
Bauer, Jens
Heitmann, Jonas S.
Maringer, Yacine
Nelde, Annika
Salih, Helmut R.
Walz, Juliane S.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS580 - TPS580
[27] Apatinib and camrelizumab plus hepatic arterial infusion with oxaliplatin and 5-fluorouracil vs. apatinib and camrelizumab as the first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A randomized multi-center clinical trial
He, Minke
Du, Zefeng
Lai, Zhicheng
Kan, Anna
Shi, Ming
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 →